Another c-Met TKI, Tivantinib (also known as ARQ 107), showed no effects in metastatic triple-negative breast cancer, but showed improved PFS in mCRPC patients in Phase 2 clinical trials [44,45]. Here, MET is linked to triple-negative breast carcinoma.